Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). The firm had revenue of $32.61 million for the quarter, compared to the consensus estimate of $41.13 million. During the same period in the previous year, the company posted ($0.14) EPS. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Akebia Therapeutics Stock Performance
AKBA stock traded up $0.05 during trading on Tuesday, reaching $1.23. 915,055 shares of the company traded hands, compared to its average volume of 3,717,157. The business has a 50 day simple moving average of $1.14 and a 200 day simple moving average of $1.38. Akebia Therapeutics has a 12 month low of $0.78 and a 12 month high of $2.48. The company has a market capitalization of $257.81 million, a price-to-earnings ratio of -5.15 and a beta of 0.77.
Analyst Ratings Changes
Get Our Latest Analysis on AKBA
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Read More
- Five stocks we like better than Akebia Therapeutics
- Airline Stocks – Top Airline Stocks to Buy Now
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Pros And Cons Of Monthly Dividend Stocks
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
